Fears over use of patient data for insurance  by Bonetta, Laura
R376 Current Biology Vol 11 No 10
Laura Bonetta reports on a US
move to restrict access to
people’s medical information but
it does not satisfy those pushing
for strong federal legislation.
A new regulation by the US
Department of Health and Human
Services will place restrictions on the
release and use of medical
information, including genetic
information, to health insurance
companies and other parties.
However, the regulation is limited in
scope and US lawmakers continue to
push for federal legislation on the
issue of genetic discrimination.
The ‘Standards for Privacy of
Individually Identifiable Health
Information’ regulation became
effective on April 14, 2001. It
requires that most health care
providers obtain their patients’
consent for use and disclosure of
health records — even for routine
disclosures such as for purposes of
treatment or payment. In addition,
patients must be given detailed
written information on their privacy
rights and how their information will
be used. From now on, an
individual’s health information can
be used, with a few exceptions, for
health purposes only. For example,
health insurance companies should
no longer be able to share medical
records with mortgage companies.
One of the limitations of the
regulation is that, while it applies to
health insurance plans and health
care providers, it does not directly
regulate many entities that hold
medical records, such as life insurers
and worker’s compensation programs.
In addition the regulation protects
privacy but does not address how
genetic information is used when
privacy is breached. 
In the past five years, several bills
addressing genetic information access
and/or use have been introduced and
re-introduced to Congress but none
have made it very far. In February of
this year Senate Democratic leader
Tom Daschle and Representative
Louise Slaughter re-introduced the
Genetic Nondiscrimination in Health
Insurance and Employment Act.
According to a spokesperson from
Slaughter’s office the act is supported
by more than 100 organizations,
ranging from the American Cancer
Society to the American Civil
Liberties Union, and has 250
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bipartisan cosponsors in the House of
Representatives (which constitutes a
majority). 
The bill, which covers all health
insurance programs, prohibits
insurers from restricting enrollment
or changing premiums on the basis of
genetic information; bans health
plans and insurers from requesting or
requiring that an individual take a
genetic test or reveal the results or a
test; and prohibits health plans and
insurers from pursuing or being
provided information on predictive
genetic information or genetic
services. In addition to insurance
companies, the bill has similar
measures in place to ban
discrimination by employers.
In a speech at the annual meeting
of the American Association for the
Advancement of Science (AAAS)
Rep. Slaughter acknowledged that
passing genetic discrimination
legislation in the US was a “daunting
challenge” given the strong
opposition from the health insurance
industry and some pharmaceutical
industries. “These industries have
extremely powerful allies in
Congress,” said Slaughter. “To date,
no standing committee of the US
House of Representatives has ever
held a hearing on genetic
discrimination issues. The chairmen
of the oversight committees have
bottled up not only my bill, but also
the entire issue. There is no doubt in
my mind that groups like health
insurers have played a key role in
those decisions.”
While the fate of federal
legislation remains to be seen, 42
states have enacted laws that provide
some level of protection against
genetic discrimination in health
insurance. Many state laws, however,
focus narrowly on DNA tests rather
than more broadly on genetic
information generated by family
history, physical examination, or
medical records. 
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